Abstract
Rheumatoid arthritis (RA) is a debilitating autoimmune disorder characterized by chronic inflammation of the synovial tissues and progressive destruction of bone and cartilage. The inflammatory response and subsequent tissue degradation are orchestrated by complex signaling networks between immune cells and their products in the blood, vascular endothelia and the connective tissue cells residing in the joints. Platelets are recognized as immune-competent cells with an important role in chronic inflammatory diseases such as RA. Here we review the specific aspects of platelet function relevant to arthritic disease, including current knowledge of the molecular crosstalk between platelets and other innate immune cells that modulate RA pathogenesis.
Introduction: RA pathophysiology
Rheumatoid arthritis (RA) is an autoimmune disease that affects ~0.4% of the global population (). The disease is characterized by chronic inflammation of the joints, degradation of bone and cartilage (), and progressive pain and loss of mobility such that 37% of RA patients become disabled (). RA decreases life expectancy and is associated with increased risk of lymphoma, cardiovascular disease, and lung cancer (, ). The precise etiology of RA is unknown, but genetic predisposition (), abnormal DNA methylation patterns (), smoking (), infection (), and gut microbiome dysbiosis () contribute to RA development. A classic hallmark of RA is the presence of the self-antigen binding anti-citrullinated protein antibodies (ACPA) that trigger chronic activation of innate immune cells. Citrullination is a protein post-translational modification where the amino acid arginine is substituted for citrulline, leading to the generation of ACPAs that initiate a pro-inflammatory response ().
During the onset of RA, the innate immune response recruits platelets and platelet microparticles (PMPs) (, ) as well as leukocytes () to the joints. PMPs and leukocytes are a source of pro-inflammatory chemokines and cytokines () that signal to the resident fibroblast-like synoviocytes (FLS) lining the synovial cavity (). FLS hyper-proliferate to form a tumor-like structure called a pannus (, ). Angiogenesis lays down new blood vessels that supply nutrients () and allow the pannus to grow until it reaches the bone and cartilage where “activated” and increasingly aggressive FLS secrete joint-destroying matrix metalloproteinases (MMP) including MMP-1, MMP-3 and MMP-13 (, ). Importantly, the distinct roles of platelets in mediating the innate immune response are now increasingly recognized in the context of RA.
Platelets are innate immune cells that drive RA pathogenesis
Platelets are small (2-3 μm) anucleate blood cells responsible for hemostasis (). Resting platelets are activated by many ligands, such as collagen and thrombin, via platelet surface receptors (Figure 1A). Activated platelets change shape, aggregate and secrete granule contents that include prothrombotic mediators, cytokines, chemokines and growth factors (), resulting in thrombus formation at the site of injury (Table 1). The process leading to activation is typically tightly regulated, allowing most platelets to circulate in their quiescent states under normal physiologic conditions. However, there is an increasing body of evidence suggesting that dysregulation of platelet activation may be a key factor in driving various chronic inflammatory diseases, including RA (101).
Figure 1
Table 1
| Mediator | Target cells | Role(s) in RA pathogenesis | Refs |
|---|---|---|---|
| CCL3 | B cell, monocyte, macrophage, neutrophil, FLS | Immune cell recruitment and activation, autoantibody production, pro-inflammatory cytokine production | (–) |
| CCL5 | Monocyte, B cell, CD4+ T cell, FLS | Immune cell recruitment and activation, pro-inflammatory cytokine production, autoantibody production | (, –) |
| CD40L & sCD40L | Neutrophil, DC, endothelial cell, B cell, FLS | Endothelium activation and leukocyte recruitment, DC maturation, angiogenesis, pro-inflammatory cytokine production, ROS production, autoantibody production | (–) |
| CXCL4 | Monocyte, macrophage, DC, neutrophil, endothelial cell, CD4+ and CD8+ T cell | Immune cell recruitment and activation, endothelium activation, ROS and pro-inflammatory cytokine production | (–) |
| CXCL7 | monocyte, neutrophil, endothelial cell | Immune cell recruitment and activation, ROS production | (, 46, , ) |
| CXCL12 | Pre-B cell, CD4+ and CD8+ T cell, Monocyte, FLS | Immune cell recruitment and activation, proinflammatory cytokine production | (, 50–53) |
| IL-1α & IL-1β | FLS, endothelial cell | Endothelial activation and immune cell recruitment, pro-inflammatory cytokine secretion, osteoclastogenesis, angiogenesis, FLS proliferation | (, , –57) |
| MMP-1 | Leukocyte | Immune cell recruitment, collagen degradation | (58, 59) |
| MMP-2 | Leukocyte | Immune cell recruitment, collagen degradation | (58, 60) |
| MMP-3 | Leukocyte | Immune cell recruitment, connective tissue degradation | (58, 61) |
| MMP-9 | Leukocyte | Immune cell recruitment (at high concentrations), inhibition of immune cell recruitment (at low concentrations) | (58) |
| PDGF | DC, FLS, macrophage | Immune cell recruitment, Treg polarization, pannus formation, cartilage degradation, inhibition of DC maturation | (56, 62–65) |
| TGF-β1 & TGF-β2 | FLS, macrophage, CD4+ T cell, B cell | Activation of immune cells, angiogenesis, cartilage degradation, osteoclastogenesis | (, 62, 66–70) |
| TSP-1 | Monocyte, macrophage, endothelial cell, neutrophil, DC, CD4+ T cell | Immune cell recruitment, Treg formation, inhibition of antigen presentation, inhibition of angiogenesis, inhibition of neutrophil elastase | (71–80) |
| VEGF | Endothelial cell, monocyte, macrophage, FLS | Angiogenesis, immune cell recruitment and activation, osteoclastogenesis | (81–84) |
| vWF | Leukocyte | Immune cell recruitment | (85, 86) |
| Glutamate | T cell, FLS | Pro-inflammatory cytokine secretion, T cell activation (at low concentrations), inhibition of T cell activation (at high concentrations) | (87–89) |
| Histamine | FLS, endothelial cell | Endothelial activation, immune cell recruitment, FLS proliferation, MMP production | (90–92) |
| NO | FLS | Inhibition of FLS apoptosis | (93, 94) |
| Serotonin | CD4+ T cell, neutrophil | Immune cell recruitment and activation, ROS production | (95–97) |
| TXA2 | Endothelial cell, FLS | Endothelium activation, FLS proliferation | (98–100) |
Platelet-derived mediators with documented role(s) in RA pathogenesis.
ADP, adenosine diphosphate; CCL, chemokine C-C motif ligand; CD, cluster of differentiation; sCD62P, soluble P-selectin; CXCL, chemokine C-X-C motif ligand; CXCL4L1, non-allelic variant of CXCL4; DC, dendritic cell; FLS, fibroblast-like synoviocyte; IL, interleukin; MMP, matrix metalloproteinase; NO, nitric oxide; PAF, platelet activating factor; PDGF, platelet-derived growth factor; PGE2, prostaglandin E2; RA, rheumatoid arthritis; ROS, reactive oxygen species; sCD40L, soluble cluster of differentiation 40 ligand; TGF, transforming growth factor; Treg, regulatory T cell; TSP-1, thrombospondin-1; TXA2, thromboxane A2; VEGF, vascular endothelial growth factor; vWF, von Willebrand factor.
A. Platelet activation and granule secretion
There are three types of platelet granules: alpha (α)-granules, dense granules, and lysosomes (reviewed in (102)). The first, and most abundant, are the α-granules that contain a multitude of cytokines, chemokines and growth factors (103). For example, α-granules release multiple pro-inflammatory molecules, including chemokine (C-C motif) ligand 5 (CCL5), soluble CD40 ligand (sCD40L/sCD154), and CXCL4 (aka platelet factor 4, PF4) (104). Furthermore, P-selectin (CD62P), a biomarker of α-granule secretion and platelet activation (105), is translocated from α-granules to the surface membrane upon platelet activation. Surface P-selectin promotes activation of leukocytes including neutrophils (see Platelet-neutrophil interactions section below). The second type of granule is the dense granule, so named due to its electron-dense appearance (102). The primary cargo of dense granules are nucleotides (adenosine diphosphate (ADP) and adenosine triphosphate (ATP)) and polyphosphates (102). Dense granule components primarily regulate platelet hemostasis and thrombosis (106). However, dense granules also release serotonin, which can promote inflammation by stimulating lymphocytes and neutrophils (95). The third type of granule is the lysosome, which contains tissue-degrading enzymes (such as collagenase) and acid phosphatase. As observed in other cell types, the key role of platelet lysosomes is to orchestrate catalytic breakdown of proteins (102).
B. Platelet extracellular vesicles
In addition to their granular contents, activated platelets release two types of extracellular vesicles: exosomes and microparticles (or microvesicles) (107). Firstly, exosomes are 30-100 nm vesicles contained within, and released with, larger intracellular vesicles. Secondly, microvesicles or platelet microparticles (PMPs) have a diameter of 100-1000 nm and are formed by the outward blebbing of the plasma membrane. PMPs are derived from the platelet plasma membrane and therefore contain the same markers found on platelet surfaces, including CD42 (glycoprotein Ib) and CD41/61 (integrin αIIbβ3) (107). Importantly, PMPs levels are increased in RA and may drive RA progression via release of their pro-inflammatory contents, e.g., interleukin-1 (IL-1) (, 107).
C. Platelets are sentinels of the innate immune system
Platelet-derived cargo molecules (Table 1) include pro-inflammatory factors linked with chronic disorders including arthritis and inflammatory bowel disease (, 108). Notably, platelets interact directly with bacteria (109), viruses (110) and complement proteins (111) and as such, are essential components of innate immunity. Platelets express toll-like receptors (TLRs) that sense pathogenic molecules (112) such as bacterial lipopolysaccharides (LPS) that induce platelet activation, aggregation, and leukocyte chemotaxis (113). Thus, platelets, as innate immune effectors, are recognized as critical mediators of RA pathogenesis (114, 115).
D. Evidence of platelet involvement in RA
Early correlational evidence suggested a role for platelets in the development and progression of RA, in that platelets were reportedly recruited to joints with their concentration in synovial fluid correlating with disease activity (, 116, 117). Later research indicated that elevated circulating platelet count (aka thrombocytosis) was associated with more severe RA (118). Subsequently, seminal research identified PMPs () in the synovial fluid of RA patients. Compared to patients with non-inflammatory arthritis, RA synovial fluid contains more IL-1-rich PMPs (). Taken together, these data indicate that platelet numbers are increased in RA, and that cytokine-laden PMPs are heavily recruited to arthritic joints.
In addition to higher platelet counts, circulating levels of platelet agonists are elevated in RA patients. For example, fibrinogen levels correlate with the number of swollen joints and overall disease activity (119). Thromboxane A2 (TXA2) is another platelet agonist whose degradation product, TXB2, is correlated with disease activity in RA (98). These data are consistent with elevated platelet activity during active RA (120). This notion is further corroborated by evidence of elevated soluble P-selectin (121) and sCD40L (122) in RA plasma. Soluble CD40L levels correlate with autoantibody levels in RA patients (123). Collectively, these data raise the possibility that platelet-derived pro-inflammatory products and cytokines play a role in propagating RA-associated joint inflammation. Animal studies provide a degree of direct evidence for the involvement of platelets in the RA pathogenesis. For example, platelet depletion prior to the induction of arthritis in mice reduces disease severity (). Therefore, understanding the precise mechanisms by which platelets drive synovial inflammation have important implications for prospective therapies.
E. Molecules upregulated in RA promote platelet activation
In addition to driving RA pathogenesis, platelets can also be reciprocally activated by molecules that are elevated in RA plasma or joint tissue. For example, a central feature of RA is the generation of ACPA and formation of immune complexes nucleated around citrullinated proteins (). Immune complexes bind and activate platelet Fc gamma receptor IIa (FcγRIIa) (124). Platelets are also activated by complement fragments (111). As such, complement activation during RA (125) can conceivably create a feedback loop through which platelet activity is continually elevated. Collectively, these data point to a two-way relationship between platelet function and innate responses in RA, where platelet-derived cytokines contribute to inflammation (Figure 1B) and ACPA-immune complexes (and other molecules) sustain platelet activation (Figure 1A). Moreover, RA-associated inflammatory mediators likely circulate and prime platelets systemically. These mechanisms may explain why RA patients are at higher risk for life-threatening complications such as deep vein thrombosis, myocardial infarction, and stroke (126, 127).
Platelet-driven signaling in the synovial tissues
A. Platelet growth factor signaling to FLS
Platelet α-granules store multiple forms of platelet-derived growth factor (PDGF) (128, 129), including the hetero and homo A/B dimers (PDGF-A/B) (130). PDGF-BB was recently confirmed to circulate in higher concentrations in RA patients (131). Furthermore, the invasiveness and proliferation of human FLS is increased following treatment with PDGF (62, 132). PDGF also promotes FLS production of pro-inflammatory cytokines IL-6, IL-8, as well as MMP-3 (133). In addition, platelets α-granules are an abundant source of transforming growth factor beta 1 (TGF-β1) (134). TGF-β1 stimulates the migratory behavior and invasiveness of cultured FLS obtained from RA patients (135). Interestingly, TGF-β reportedly acts synergistically along with PDGF to trigger FLS proliferation and a pro-inflammatory phenotype (132, 133). Collectively, these data provide both clinical and in vitro evidence of how synovial inflammation is likely propagated by platelet growth factors.
B. Platelet-derived cytokines and FLS
In addition to growth factors, platelet granules release several pro-inflammatory cytokines that exacerbate RA disease activity (Table 1). For example, platelets release copious quantities of CCL5 (RANTES) (). CCL5 drives RA pathogenesis by upregulating MMPs in RA FLS (136). Activated platelets also secrete IL-1β (, ). IL-1β promotes synovial inflammation and RA progression by upregulating RANKL expression by FLS (55), which, in turn drives osteoclastogenesis and bone resorption (137). PMPs are another source of IL-1α (), IL-1β (), CCL5 (138), and sCD40L (139). Moreover, the role of PMPs in RA is supported by the observation that they increase the invasiveness and motility of cultured FLS (140, 141). Taken together, the evidence supports a role for platelet-derived cytokines and PMPs in synovial tissue degradation by promoting the release of MMPs and additional pro-inflammatory cytokines from FLS.
Interplay between platelets and other elements of the innate immune system
In addition to modulating disease by signaling to FLS, platelets interface directly with several other aspects of the innate immune system (Figure 1B). Platelets activate complement proteins and recruit leukocytes to the joint tissues. Multiple lines of evidence suggest that the pro-inflammatory leukocyte phenotype is enhanced via association with platelets. Here we detail the interactions between platelets and other aspects of the innate immune system that could explain the molecular basis underpinning the contribution of platelets to RA.
A. Platelet-neutrophil interactions
Platelets promote neutrophil chemotaxis
A feature of RA pathogenesis is the marked influx of immune cells, including neutrophils, into the synovium (). Evidence from human (142) and murine (143) studies indicate that neutrophils are important for RA development by participating in joint tissue degradation and by releasing proinflammatory cytokines that further exacerbate RA (144, 145). Platelets can potentially recruit neutrophils into the joint by four possible mechanisms. Firstly, platelet-derived serotonin (95) and CXCL7 (146) are direct neutrophil chemoattractants; platelets stimulate FLS to secrete IL-8, CXCL2, and CXCL3 (147), all of which attract neutrophils (148); PMPs also recruit neutrophils to the joints (149). Secondly, exposed P-selectin on the platelet surface facilitates neutrophil adhesion via P-selectin glycoprotein ligand 1 (PSGL1) on the neutrophil surface (150). Thirdly, platelet-derived membrane-bound platelet activating factor (PAF) activates the neutrophil PAF receptor, leading to the activation of CD18 on the neutrophil surface (151). Neutrophil CD11b/CD18 (aka Mac-1) can then bind to glycoprotein Ibα (GPIbα) on the platelets (152). Finally, both neutrophil-derived CD11b/CD18 (153) and platelet-derived integrin αIIbβ3 (154) bind fibrinogen; CD11b/CD18 and αIIbβ3 can therefore mediate platelet-neutrophil adhesion via fibrinogen. These data provide compelling evidence of platelet-neutrophil crosstalk that can drive RA pathogenesis.
Platelets promote NET formation
Another central feature of neutrophils in the innate immune response is the release of neutrophil extracellular traps (NETs) consisting of genomic DNA, proteolytic enzymes, and reactive oxygen species (ROS) (155). NETs contribute to self-protein citrullination and correlate with ACPA levels (142) (Figure 1C). Platelets colocalize with degranulated neutrophils and NETs in coronary thrombi (156). Moreover, platelet depletion restricts NET formation in mouse models of endotoxemia (157). Activated platelets releases cytosolic stores of the alarmin high mobility group box 1 protein (HMGB1) that activates receptor for advanced glycation end products (RAGE) expressed on the surface of neutrophils, causing neutrophil autophagy and subsequent NET formation (156). These evidences implicate platelets as pivotal supporters of neutrophil-mediated inflammation and tissue degradation in RA.
B. Platelets interactions with the complement system
The complement system is an essential component of the innate immune response and is comprised of 9 serum proteins (C1-C9) activated sequentially, culminating in the formation of the membrane attack complex (MAC) that eliminates pathogens but is also implicated in autoimmune pathogenesis [reviewed in (158)]. There exist three separate pathways to complement activation: the classical pathway (elicited by binding of immunoglobulin to C1), the alternative pathway (triggered by the hydrolysis of C3 producing C3-H2O) and the lectin pathway (111).
Considerable evidence implicates complement activation as a contributing factor in RA [recently reviewed in (159)]. For example, MAC is upregulated in RA serum and synovial fluid (125), while an endogenous inhibitor of MAC, CD59, is downregulated in RA synovium (160). In addition, the role of complement proteins in neutrophil activation (161) is likely related to RA progression since neutrophils contribute to tissue degradation (144, 145) (Figure 1C).
Platelets contribute to complement activation in multiple ways. For example, a leukocyte-derived molecule termed properdin binds the platelet plasma membrane and recruits C3(H2O) thus activating the alternative pathway (162). Moreover, P-selectin on activated platelets binds C3b (163). Activated platelets also bind ficolin, which stimulates the lectin pathway (164). The evidence collectively supports a role for platelets in RA pathogenesis via the complement system.
C. Platelet interactions with monocytes/macrophages
Macrophages phagocytose invading pathogens and as such are critical elements of the innate immune response. As reviewed by Ley (165), macrophages may be polarized to a proinflammatory (M1) or an anti-inflammatory (M2) phenotype; in addition, M1 macrophages exacerbate bone degradation in RA. Accordingly, the number of macrophages in the synovium correlates with RA severity in humans (166), and depletion of monocytes attenuates the development of experimental murine arthritis (167).
Platelets and monocyte chemotaxis
As is observed with neutrophils, platelets serve to recruit monocytes. First, monocytes adhere to endothelium-bound platelets through the interaction between platelet surface P-selectin and PSGL1 expressed on the monocyte surface (168). Second, platelet-derived molecules promote adhesion between monocytes and the endothelium. Platelet-derived CCL5, CXCL4 (platelet factor 4, PF4), and CXCL7 promote monocyte chemotaxis as well as monocyte-endothelium adhesion (). These chemokines and the anaphylatoxin C5a (generated by platelet-induced complement activation) upregulate CD11b (169), β1 integrin (170), and CD18 (β2 integrin) (170) on the monocyte surface. CD11b/CD18, which is expressed by monocytes (168), binds to platelet-derived junction adhesion molecule C (JAMC/JAM3) (171) and GPIbα (172) to facilitate firm adhesion.
Platelet-monocyte interactions
Once inside the joint, platelet-monocyte interactions contribute to joint pathology. In vitro experiments show that PAF, P-selectin, and CCL5 (RANTES) induce the secretion of CCL2, TNF-α, and IL-8 from monocytes (, 173); these mediators can then in turn upregulate inflammation in the joint. Moreover, CXCL4 (PF4), a major platelet-derived chemokine, polarizes macrophages to an M4 subtype (distinct from M1 and M2 subtypes) that secretes pro-inflammatory TNF-α () and generates reactive oxygen species (ROS) (). In addition, the differentiation of monocytes into bone-resorbing osteoclasts is accentuated by platelet-derived TGF-β1 (66). Taken together, these data illuminate multiple pathways through which platelets could promote synovial inflammation through interactions with monocytes/macrophages.
D. Platelet interactions with dendritic cells
Dendritic cells (DCs) are immune cells whose morphology is characterized by tree-like (dendritic) processes (174). Activated dendritic cells present pathogen-derived antigens to T cells, thus acting as a bridge between the innate and adaptive immune responses (175). Evidence suggests that DCs play an important role in RA (176). As is the case with neutrophils and monocytes, evidence supports a potential role for platelets in recruiting DCs. For example, in vitro data indicate that platelet-derived P-selectin and JAMC bind to PSGL1 and CD11b/CD18 expressed on DCs to promote platelet-DC adhesion (). However, the platelets’ effects on DCs in disease are ambiguous since platelet-DC interactions can either promote or dampen inflammation. Platelet-derived sCD40L and CXCL4 (PF4) induce DC maturation, pro-inflammatory cytokine secretion from DCs, and interferon-α (IFN-α) secretion from stimulated plasmacytoid DCs (pDCs) in vitro (, 177, 178). IFN-α causes DCs to secrete more TNF-α upon TLR4 stimulation, exacerbating RA (179). However, IFN-α can induce the polarization of both pro-inflammatory (180) and anti-inflammatory (181) T-cells, which can worsen or alleviate RA. Moreover, platelets also influence DC-mediated proliferation of T-cells () although it is not clear whether these T-cells adopt a pro-inflammatory (Th1/Th17) or anti-inflammatory regulatory (Treg) phenotype (Figure 1C). Further research is required to clarify the significance of DC cell function in RA pathogenesis and determine how DC function could be regulated through interactions with platelets.
E. Platelet interactions with innate lymphoid cells
Innate lymphoid cells (ILCs) include five subsets of antigen-independent effector and helper cells that mirror the phenotypes of T-cell subsets (182). This group includes natural killer (NK) cells, lymphoid tissue inducer (LTi) cells and three subtypes of innate lymphoid ‘helper-like’ cells [ILC1, ILC2 and ILC3, reviewed in (183)]. ILCs have developmental, tissue-specific, and context-dependent roles in immunity with considerable phenotypic heterogeneity that are still under investigation (183, 184). Thus, the full picture of ILC biology, particularly in the context of RA [recently reviewed in (185)], is incomplete. Generally, the ILC subsets (NK/ILC1, LTi, ILC3 cells) that promote Th1/Th17-like responses, M1-macrophage polarization or recruitment of neutrophils likely exacerbate RA (185). Conversely, ILC2s, which promote Th2/Treg-like immunity, M2-polarization, and recruitment of eosinophils likely attenuate RA severity (185).
The role of platelets in modulating ILC function is poorly understood. ILC2 cell counts are elevated in the circulation and the synovial fluid of RA patients compared to healthy controls although their presence was inversely correlated with disease severity (186). In mouse models of arthritis, ILC2 appear to diminish inflammation and bone destruction (186). Limited data are available regarding platelet interactions with ILC2 cells. Naïve ILC2 cells express PSGL-1 and adhere to platelets in murine lung tissue, presumably via P-selectin on the platelet surface (187, 188). This interaction maintains elevated ILC2 numbers in naïve lung, enhances response to IL-33, amplifies production of Th2-cytokines (IL-5 and IL-13) and, exacerbates lung inflammation in response to Alternaria (fungus) (187, 188). While documented ILC2-platelet adhesion is limited to lung tissue thus far (187), platelet-ILC2 interactions in the synovium could also conceivably attenuate RA. It is tempting to speculate that platelet-derived mediators would recruit and/or activate most ILC subsets, however, considerable further research is required to identify relevant platelet-ILC interactions in the synovium.
Perspectives
Considerable evidence now indicates that activated platelets participate in pro-inflammatory signaling in the synovial tissues, in part through activating other cellular elements of the innate immune system. However, pro-inflammatory molecules in RA also potentiate platelet activity, suggesting a reciprocal relationship between RA and platelet activation. Platelets are therefore well-positioned to occupy a central role in RA pathogenesis as it relates to the innate immune response. Indeed, the concept of platelets as a therapeutic target for RA has been explored (189) although due to the nature of many of the currently available antiplatelet drugs, it may be difficult to exploit the anti-inflammatory effects without conferring increased bleeding risks. Moreover, the sheer complexity of the biological system (Figure 1B) highlights the challenges associated with pinpointing the most clinically significant platelet-centric signaling pathways in RA. Since multiple pro-inflammatory cytokines are expressed in more than one tissue type, future research could employ experimental murine models with platelet-specific conditional knockouts of specific cytokines (and/or their cognate receptors). Such an approach could identify the exact contributions of specific platelet-derived molecules to RA pathogenesis. This information would then be applicable for identifying viable platelet-based therapeutic targets that could reduce disease severity, and mitigate the increased risk of cardiovascular complications resulting from RA.
Funding
This work was supported by a Canadian Institutes of Health Research (CIHR) Operating Grant (MY4-155400) and a Michael Smith Foundation for Health Research (MSFHR) Scholar Award (to HK).
Acknowledgments
The authors thank Angela Tether for editorial assistance. JT and SJ acknowledge support from a Graduate Student Award Program from the UBC Centre for Blood Research. SJ also acknowledges support from the UBC International Tuition Award.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Statements
Author contributions
SJ wrote the first draft of the manuscript. JT, MH, KM and HK designed the concept and layout of the manuscript and/or wrote sections of the manuscript. All authors contributed to the article and approved the submitted version.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1
RudanISidhuSPapanaAMengSJXin-WeiYWangWet al. Prevalence of rheumatoid arthritis in low- and middle-income countries: A systematic review and analysis. J Glob Health (2015) 5(1):010409.
2
SmolenJSAletahaDMcInnesIB. Rheumatoid arthritis. Lancet (2016) 388(10055):2023–38. doi: 10.1016/S0140-6736(16)30173-8
3
SokkaTKautiainenHPincusTVerstappenSMAggarwalAAltenRet al. Work disability remains a major problem in rheumatoid arthritis in the 2000s: Data from 32 countries in the QUEST-RA study. Arthritis Res Ther (2010) 12(2):R42. doi: 10.1186/ar2951
4
ChiuYMLuYPLanJLChenDYWangJD. Lifetime risks, life expectancy, and health care expenditures for rheumatoid arthritis: A nationwide cohort followed up from 2003 to 2016. Arthritis Rheumatol (2021) 73(5):750–8. doi: 10.1002/art.41597
5
McInnesIBSchettG. The pathogenesis of rheumatoid arthritis. N Engl J Med (2011) 365(23):2205–19. doi: 10.1056/NEJMra1004965
6
KimKBangSYLeeHSBaeSC. Update on the genetic architecture of rheumatoid arthritis. Nat Rev Rheumatol (2017) 13(1):13–24. doi: 10.1038/nrrheum.2016.176
7
LiuYAryeeMJPadyukovLFallinMDHesselbergERunarssonAet al. Epigenome-wide association data implicate DNA methylation as an intermediary of genetic risk in rheumatoid arthritis. Nat Biotechnol (2013) 31(2):142–7. doi: 10.1038/nbt.2487
8
SilmanAJNewmanJMacGregorAJ. Cigarette smoking increases the risk of rheumatoid arthritis. Results from a nationwide study of disease-discordant twins. Arthritis Rheumatol (1996) 39(5):732–5.
9
WegnerNWaitRSrokaAEickSNguyenKALundbergKet al. Peptidylarginine deiminase from porphyromonas gingivalis citrullinates human fibrinogen and alpha-enolase: implications for autoimmunity in rheumatoid arthritis. Arthritis Rheumatol (2010) 62(9):2662–72. doi: 10.1002/art.27552
10
ScherJULittmanDRAbramsonSB. Microbiome in inflammatory arthritis and human rheumatic diseases. Arthritis Rheumatol (2016) 68(1):35–45. doi: 10.1002/art.39259
11
AliverniniSGaleazziMPelegHTolussoBGremeseEFerraccioliGet al. Is ACPA positivity the main driver for rheumatoid arthritis treatment? pros and cons. Autoimmun Rev (2017) 16(11):1096–102. doi: 10.1016/j.autrev.2017.09.002
12
BoilardENigrovicPALarabeeKWattsGFCoblynJSWeinblattMEet al. Platelets amplify inflammation in arthritis via collagen-dependent microparticle production. Science. (2010) 327(5965):580–3. doi: 10.1126/science.1181928
13
FarrMWainwrightASalmonMHollywellCABaconPA. Platelets in the synovial fluid of patients with rheumatoid arthritis. Rheumatol Int (1984) 4(1):13–7. doi: 10.1007/BF00683878
14
WrightHLLyonMChapmanEAMootsRJEdwardsSW. Rheumatoid arthritis synovial fluid neutrophils drive inflammation through production of chemokines, reactive oxygen species, and neutrophil extracellular traps. Front Immunol (2020) 11:584116. doi: 10.3389/fimmu.2020.584116
15
LiuWZhangYZhuWMaCRuanJLongHet al. Sinomenine inhibits the progression of rheumatoid arthritis by regulating the secretion of inflammatory cytokines and Monocyte/Macrophage subsets. Front Immunol (2018) 9:2228. doi: 10.3389/fimmu.2018.02228
16
BartokBFiresteinGS. Fibroblast-like synoviocytes: Key effector cells in rheumatoid arthritis. Immunol Rev (2010) 233(1):233–55. doi: 10.1111/j.0105-2896.2009.00859.x
17
Garcia-VicunaRGomez-GaviroMVDominguez-LuisMJPecMKGonzalez-AlvaroIAlvaro-GraciaJMet al. CC and CXC chemokine receptors mediate migration, proliferation, and matrix metalloproteinase production by fibroblast-like synoviocytes from rheumatoid arthritis patients. Arthritis Rheumatol (2004) 50(12):3866–77. doi: 10.1002/art.20615
18
YouSKohJHLengLKimWUBucalaR. The tumor-like phenotype of rheumatoid synovium: Molecular profiling and prospects for precision medicine. Arthritis Rheumatol (2018) 70(5):637–52. doi: 10.1002/art.40406
19
ClemetsonKJ. Platelets and primary haemostasis. Thromb Res (2012) 129(3):220–4. doi: 10.1016/j.thromres.2011.11.036
20
GolebiewskaEMPooleAW. Platelet secretion: From haemostasis to wound healing and beyond. Blood Rev (2015) 29(3):153–62. doi: 10.1016/j.blre.2014.10.003
21
KlingerMHWilhelmDBubelSSticherlingMSchroderJMKuhnelW. Immunocytochemical localization of the chemokines RANTES and MIP-1 alpha within human platelets and their release during storage. Int Arch Allergy Immunol (1995) 107(4):541–6. doi: 10.1159/000237097
22
ZhaoXGuMXuXWenXYangGLiLet al. CCL3/CCR1 mediates CD14(+)CD16(-) circulating monocyte recruitment in knee osteoarthritis progression. Osteoarthr Cartilage (2020) 28(5):613–25. doi: 10.1016/j.joca.2020.01.009
23
KimataHYoshidaAIshiokaCFujimotoMLindleyIFurushoK. RANTES and macrophage inflammatory protein 1 alpha selectively enhance immunoglobulin (IgE) and IgG4 production by human b cells. J Exp Med (1996) 183(5):2397–402. doi: 10.1084/jem.183.5.2397
24
ReichelCARehbergMLerchenbergerMBerberichNBihariPKhandogaAGet al. Ccl2 and Ccl3 mediate neutrophil recruitment via induction of protein synthesis and generation of lipid mediators. Arterioscler Thromb Vasc Biol (2009) 29(11):1787–93. doi: 10.1161/ATVBAHA.109.193268
25
ZhangGLiuHBZhouLCuiXQFanXH. CCL3 participates in the development of rheumatoid arthritis by activating AKT. Eur Rev Med Pharmacol Sci (2018) 22(20):6625–32.
26
von HundelshausenPWeberKSHuoYProudfootAENelsonPJLeyKet al. RANTES deposition by platelets triggers monocyte arrest on inflamed and atherosclerotic endothelium. Circulation (2001) 103(13):1772–7. doi: 10.1161/01.CIR.103.13.1772
27
WeyrichASElstadMRMcEverRPMcIntyreTMMooreKLMorrisseyJHet al. Activated platelets signal chemokine synthesis by human monocytes. J Clin Invest (1996) 97(6):1525–34. doi: 10.1172/JCI118575
28
MachlusKRJohnsonKEKulenthirarajanRForwardJATippyMDSoussouTSet al. CCL5 derived from platelets increases megakaryocyte proplatelet formation. Blood (2016) 127(7):921–6. doi: 10.1182/blood-2015-05-644583
29
GilatDHershkovizRMekoriYAVlodavskyILiderO. Regulation of adhesion of CD4+ T lymphocytes to intact or heparinase-treated subendothelial extracellular matrix by diffusible or anchored RANTES and MIP-1 beta. J Immunol (1994) 153(11):4899–906.
30
NankiTNagasakaKHayashidaKSaitaYMiyasakaN. Chemokines regulate IL-6 and IL-8 production by fibroblast-like synoviocytes from patients with rheumatoid arthritis. J Immunol (2001) 167(9):5381–5. doi: 10.4049/jimmunol.167.9.5381
31
HennVSlupskyJRGrafeMAnagnostopoulosIForsterRMuller-BerghausGet al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature (1998) 391(6667):591–4. doi: 10.1038/35393
32
KhanSYKelherMRHealJMBlumbergNBoshkovLKPhippsRet al. Soluble CD40 ligand accumulates in stored blood components, primes neutrophils through CD40, and is a potential cofactor in the development of transfusion-related acute lung injury. Blood (2006) 108(7):2455–62. doi: 10.1182/blood-2006-04-017251
33
CzapigaMKirkADLekstrom-HimesJ. Platelets deliver costimulatory signals to antigen-presenting cells: A potential bridge between injury and immune activation. Exp Hematol (2004) 32(2):135–9. doi: 10.1016/j.exphem.2003.11.004
34
XuHZhangXMannonRBKirkAD. Platelet-derived or soluble CD154 induces vascularized allograft rejection independent of cell-bound CD154. J Clin Invest (2006) 116(3):769–74. doi: 10.1172/JCI27155
35
ArmitageRJFanslowWCStrockbineLSatoTACliffordKNMacduffBMet al. Molecular and biological characterization of a murine ligand for CD40. Nature (1992) 357(6373):80–2. doi: 10.1038/357080a0
36
ChoCSChoMLMinSYKimWUMinDJLeeSSet al. CD40 engagement on synovial fibroblast up-regulates production of vascular endothelial growth factor. J Immunol (2000) 164(10):5055–61. doi: 10.4049/jimmunol.164.10.5055
37
BaltusTvon HundelshausenPMauseSFBuhreWRossaintRWeberC. Differential and additive effects of platelet-derived chemokines on monocyte arrest on inflamed endothelium under flow conditions. J Leukoc Biol (2005) 78(2):435–41. doi: 10.1189/jlb.0305141
38
ScheuererBErnstMDurrbaum-LandmannIFleischerJGrage-GriebenowEBrandtEet al. The CXC-chemokine platelet factor 4 promotes monocyte survival and induces monocyte differentiation into macrophages. Blood (2000) 95(4):1158–66. doi: 10.1182/blood.V95.4.1158.004k31_1158_1166
39
KasperBBrandtEBrandauSPetersenF. Platelet factor 4 (CXC chemokine ligand 4) differentially regulates respiratory burst, survival, and cytokine expression of human monocytes by using distinct signaling pathways. J Immunol (2007) 179(4):2584–91. doi: 10.4049/jimmunol.179.4.2584
40
LangerHFDaubKBraunGSchonbergerTMayAESchallerMet al. Platelets recruit human dendritic cells via mac-1/JAM-C interaction and modulate dendritic cell function in vitro. Arterioscler Thromb Vasc Biol (2007) 27(6):1463–70. doi: 10.1161/ATVBAHA.107.141515
41
Briquet-LaugierVLavenu-BombledCSchmittALeboeufMUzanGDubart-KupperschmittAet al. Probing platelet factor 4 alpha-granule targeting. J Thromb Haemost (2004) 2(12):2231–40. doi: 10.1111/j.1538-7836.2004.01037.x
42
von HundelshausenPKoenenRRSackMMauseSFAdriaensWProudfootAEet al. Heterophilic interactions of platelet factor 4 and RANTES promote monocyte arrest on endothelium. Blood (2005) 105(3):924–30. doi: 10.1182/blood-2004-06-2475
43
WollerGBrandtEMittelstadtJRybakowskiCPetersenF. Platelet factor 4/CXCL4-stimulated human monocytes induce apoptosis in endothelial cells by the release of oxygen radicals. J Leukoc Biol (2008) 83(4):936–45. doi: 10.1189/jlb.0907592
44
SrivastavaKCockburnIASwaimAThompsonLETripathiAFletcherCAet al. Platelet factor 4 mediates inflammation in experimental cerebral malaria. Cell Host Microbe (2008) 4(2):179–87. doi: 10.1016/j.chom.2008.07.003
45
AzizKACawleyJCZuzelM. via released PF4: Mechanism of priming and synergy with GM-CSF. Br J Haematol (1995) 91(4):846–53. doi: 10.1111/j.1365-2141.1995.tb05399.x
46
SchenkBIPetersenFFladHDBrandtE. Platelet-derived chemokines CXC chemokine ligand (CXCL)7, connective tissue-activating peptide III, and CXCL4 differentially affect and cross-regulate neutrophil adhesion and transendothelial migration. J Immunol (2002) 169(5):2602–10. doi: 10.4049/jimmunol.169.5.2602
47
YuGRuxAHMaPBdeirKSachaisBS. Endothelial expression of e-selectin is induced by the platelet-specific chemokine platelet factor 4 through LRP in an NF-kappaB-dependent manner. Blood (2005) 105(9):3545–51. doi: 10.1182/blood-2004-07-2617
48
ZhangYMaKLGongYXWangGHHuZBLiuLet al. Platelet microparticles mediate glomerular endothelial injury in early diabetic nephropathy. J Am Soc Nephrol (2018) 29(11):2671–95. doi: 10.1681/ASN.2018040368
49
WalzADewaldBvon TscharnerVBaggioliniM. Effects of the neutrophil-activating peptide NAP-2, platelet basic protein, connective tissue-activating peptide III and platelet factor 4 on human neutrophils. J Exp Med (1989) 170(5):1745–50. doi: 10.1084/jem.170.5.1745
50
MassbergSKonradISchurzingerKLorenzMSchneiderSZohlnhoeferDet al. Platelets secrete stromal cell-derived factor 1alpha and recruit bone marrow-derived progenitor cells to arterial thrombi in vivo. J Exp Med (2006) 203(5):1221–33. doi: 10.1084/jem.20051772
51
NagasawaTKikutaniHKishimotoT. Molecular cloning and structure of a pre-b-cell growth-stimulating factor. Proc Natl Acad Sci U S A (1994) 91(6):2305–9. doi: 10.1073/pnas.91.6.2305
52
Dunussi-JoannopoulosKZuberekKRunyonKHawleyRGWongAEricksonJet al. Efficacious immunomodulatory activity of the chemokine stromal cell-derived factor 1 (SDF-1): Local secretion of SDF-1 at the tumor site serves as T-cell chemoattractant and mediates T-cell-dependent antitumor responses. Blood (2002) 100(5):1551–8. doi: 10.1182/blood.V100.5.1551.h81702001551_1551_1558
53
ChatterjeeMvon Ungern-SternbergSNSeizerPSchlegelFButtcherMSindhuNAet al. Platelet-derived CXCL12 regulates monocyte function, survival, differentiation into macrophages and foam cells through differential involvement of CXCR4-CXCR7. Cell Death Dis (2015) 6:e1989. doi: 10.1038/cddis.2015.233
54
LindemannSTolleyNDDixonDAMcIntyreTMPrescottSMZimmermanGAet al. Activated platelets mediate inflammatory signaling by regulated interleukin 1beta synthesis. J Cell Biol (2001) 154(3):485–90. doi: 10.1083/jcb.200105058
55
HashizumeMHayakawaNMiharaM. IL-6 trans-signalling directly induces RANKL on fibroblast-like synovial cells and is involved in RANKL induction by TNF-alpha and IL-17. Rheumatol (Oxford) (2008) 47(11):1635–40. doi: 10.1093/rheumatology/ken363
56
BergstromBCarlstenHEkwallAH. Methotrexate inhibits effects of platelet-derived growth factor and interleukin-1beta on rheumatoid arthritis fibroblast-like synoviocytes. Arthritis Res Ther (2018) 20(1):49.
57
BustosMSaadiSPlattJL. Platelet-mediated activation of endothelial cells: Implications for the pathogenesis of transplant rejection. Transplantation (2001) 72(3):509–15. doi: 10.1097/00007890-200108150-00025
58
ChungAWRadomskiAAlonso-EscolanoDJuraszPStewartMWMalinskiTet al. Platelet-leukocyte aggregation induced by PAR agonists: regulation by nitric oxide and matrix metalloproteinases. Br J Pharmacol (2004) 143(7):845–55. doi: 10.1038/sj.bjp.0705997
59
WilliamsKEOlsenDR. Matrix metalloproteinase-1 cleavage site recognition and binding in full-length human type III collagen. Matrix Biol (2009) 28(6):373–9. doi: 10.1016/j.matbio.2009.04.009
60
RastogiAKimHTwomeyJDHsiehAH. MMP-2 mediates local degradation and remodeling of collagen by annulus fibrosus cells of the intervertebral disc. Arthritis Res Ther (2013) 15(2):R57. doi: 10.1186/ar4224
61
OkadaYNagaseHHarrisEDJr.A metalloproteinase from human rheumatoid synovial fibroblasts that digests connective tissue matrix components. purification and characterization. J Biol Chem (1986) 261(30):14245–55.
62
CharbonneauMLavoieRRLauzierAHarperKMcDonaldPPDuboisCM. Platelet-derived growth factor receptor activation promotes the prodestructive invadosome-forming phenotype of synoviocytes from patients with rheumatoid arthritis. J Immunol (2016) 196(8):3264–75. doi: 10.4049/jimmunol.1500502
63
WestermarkBWastesonA. A platelet factor stimulating human normal glial cells. Exp Cell Res (1976) 98(1):170–4. doi: 10.1016/0014-4827(76)90476-6
64
AgrawalSGangulySHajianPCaoJNAgrawalA. PDGF upregulates CLEC-2 to induce T regulatory cells. Oncotarget (2015) 6(30):28621–32. doi: 10.18632/oncotarget.5765
65
KrettekAOstergren-LundenGFagerGRosmondCBondjersGLustigF. Expression of PDGF receptors and ligand-induced migration of partially differentiated human monocyte-derived macrophages. influence of IFN-gamma and TGF-beta. Atherosclerosis (2001) 156(2):267–75.
66
WeichtBMaitzPKandlerBFischerMBWatzekGGruberR. Activated platelets positively regulate RANKL-mediated osteoclast differentiation. J Cell Biochem (2007) 102(5):1300–7. doi: 10.1002/jcb.21360
67
AssoianRKKomoriyaAMeyersCAMillerDMSpornMB. Transforming growth factor-beta in human platelets. identification of a major storage site, purification, and characterization. J Biol Chem (1983) 258(11):7155–60.
68
CheifetzSWeatherbeeJATsangMLAndersonJKMoleJELucasRet al. The transforming growth factor-beta system, a complex pattern of cross-reactive ligands and receptors. Cell (1987) 48(3):409–15. doi: 10.1016/0092-8674(87)90192-9
69
TakimotoTWakabayashiYSekiyaTInoueNMoritaRIchiyamaKet al. Smad2 and Smad3 are redundantly essential for the TGF-beta-mediated regulation of regulatory T plasticity and Th1 development. J Immunol (2010) 185(2):842–55. doi: 10.4049/jimmunol.0904100
70
EhrhardtROStroberWHarrimanGR. Effect of transforming growth factor (TGF)-beta 1 on IgA isotype expression. TGF-beta 1 induces a small increase in sIgA+ b cells regardless of the method of b cell activation. J Immunol (1992) 148(12):3830–6.
71
LawlerJWSlayterHSColiganJE. Isolation and characterization of a high molecular weight glycoprotein from human blood platelets. J Biol Chem (1978) 253(23):8609–16. doi: 10.1016/S0021-9258(17)34336-3
72
SilversteinRLNachmanRL. Thrombospondin binds to monocytes-macrophages and mediates platelet-monocyte adhesion. J Clin Invest (1987) 79(3):867–74. doi: 10.1172/JCI112896
73
JimenezBVolpertOVCrawfordSEFebbraioMSilversteinRLBouckN. Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1. Nat Med (2000) 6(1):41–8. doi: 10.1038/71517
74
TarabolettiGBelottiDBorsottiPVerganiVRusnatiMPrestaMet al. The 140-kilodalton antiangiogenic fragment of thrombospondin-1 binds to basic fibroblast growth factor. Cell Growth Differ (1997) 8(4):471–9.
75
MansfieldPJBoxerLASuchardSJ. Thrombospondin stimulates motility of human neutrophils. J Cell Biol (1990) 111(6 Pt 2):3077–86. doi: 10.1083/jcb.111.6.3077
76
HoggPJOwensbyDAMosherDFMisenheimerTMChestermanCN. Thrombospondin is a tight-binding competitive inhibitor of neutrophil elastase. J Biol Chem (1993) 268(10):7139–46. doi: 10.1016/S0021-9258(18)53157-4
77
GrimbertPBouguermouhSBabaNNakajimaTAllakhverdiZBraunDet al. Thrombospondin/CD47 interaction: A pathway to generate regulatory T cells from human CD4+ CD25- T cells in response to inflammation. J Immunol (2006) 177(6):3534–41. doi: 10.4049/jimmunol.177.6.3534
78
LamyLFoussatABrownEJBornsteinPTicchioniMBernardA. Interactions between CD47 and thrombospondin reduce inflammation. J Immunol (2007) 178(9):5930–9. doi: 10.4049/jimmunol.178.9.5930
79
DoyenVRubioMBraunDNakajimaTAbeJSaitoHet al. Thrombospondin 1 is an autocrine negative regulator of human dendritic cell activation. J Exp Med (2003) 198(8):1277–83. doi: 10.1084/jem.20030705
80
SabanDRBockFChauhanSKMasliSDanaR. Thrombospondin-1 derived from APCs regulates their capacity for allosensitization. J Immunol (2010) 185(8):4691–7. doi: 10.4049/jimmunol.1001133
81
MaloneyJPSillimanCCAmbrusoDRWangJTuderRMVoelkelNF. In vitro release of vascular endothelial growth factor during platelet aggregation. American Journal of Physiology-Heart and Circulatory Physiology (1998) 275(3):H1054–61.
82
del ReyMJIzquierdoECajaSUsateguiASantiagoBGalindoMet al. Human inflammatory synovial fibroblasts induce enhanced myeloid cell recruitment and angiogenesis through a hypoxia-inducible transcription factor 1alpha/vascular endothelial growth factor-mediated pathway in immunodeficient mice. Arthritis Rheumatol (2009) 60(10):2926–34.
83
MatsumotoYTanakaKHirataGHanadaMMatsudaSShutoTet al. Possible involvement of the vascular endothelial growth factor-Flt-1-focal adhesion kinase pathway in chemotaxis and the cell proliferation of osteoclast precursor cells in arthritic joints. J Immunol (2002) 168(11):5824–31. doi: 10.4049/jimmunol.168.11.5824
84
KimHRKimKWKimBMChoMLLeeSH. The effect of vascular endothelial growth factor on osteoclastogenesis in rheumatoid arthritis. PLoS One (2015) 10(4):e0124909. doi: 10.1371/journal.pone.0124909
85
MaynardDMHeijnenHFHorneMKWhiteJGGahlWA. Proteomic analysis of platelet alpha-granules using mass spectrometry. J Thromb Haemost (2007) 5(9):1945–55. doi: 10.1111/j.1538-7836.2007.02690.x
86
ChauhanAKKisuckaJBrillAWalshMTScheiflingerFWagnerDD. ADAMTS13: A new link between thrombosis and inflammation. J Exp Med (2008) 205(9):2065–74. doi: 10.1084/jem.20080130
87
TremolizzoLDiFrancescoJCRodriguez-MenendezVSirtoriELongoniMCassettiAet al. Human platelets express the synaptic markers VGLUT1 and 2 and release glutamate following aggregation. Neurosci Lett (2006) 404(3):262–5. doi: 10.1016/j.neulet.2006.06.015
88
SarchielliPDi FilippoMCandeliereAChiasseriniDMattioniATenagliaSet al. Expression of ionotropic glutamate receptor GLUR3 and effects of glutamate on MBP- and MOG-specific lymphocyte activation and chemotactic migration in multiple sclerosis patients. J Neuroimmunol (2007) 188(1-2):146–58. doi: 10.1016/j.jneuroim.2007.05.021
89
FloodSParriRWilliamsADuanceVMasonD. Modulation of interleukin-6 and matrix metalloproteinase 2 expression in human fibroblast-like synoviocytes by functional ionotropic glutamate receptors. Arthritis Rheumatol (2007) 56(8):2523–34. doi: 10.1002/art.22829
90
MasiniEDi BelloMGRaspantiSNdisangJFBarontiRCappugiPet al. The role of histamine in platelet aggregation by physiological and immunological stimuli. Inflammation Res (1998) 47(5):211–20. doi: 10.1007/s000110050319
91
ZenmyoMHiraokaKKomiyaSMorimatsuMSasaguriY. Histamine-stimulated production of matrix metalloproteinase 1 by human rheumatoid synovial fibroblasts is mediated by histamine H1-receptors. Virchows Arch (1995) 427(4):437–44. doi: 10.1007/BF00199394
92
AsakoHKuroseIWolfRDeFreesSZhengZLPhillipsMLet al. Role of H1 receptors and p-selectin in histamine-induced leukocyte rolling and adhesion in postcapillary venules. J Clin Invest (1994) 93(4):1508–15. doi: 10.1172/JCI117129
93
MehtaJLChenLYKoneBCMehtaPTurnerP. Identification of constitutive and inducible forms of nitric oxide synthase in human platelets. J Lab Clin Med (1995) 125(3):370–7.
94
MigitaKYamasakiSKitaMIdaHShibatomiKKawakamiAet al. Nitric oxide protects cultured rheumatoid synovial cells from fas-induced apoptosis by inhibiting caspase-3. Immunology (2001) 103(3):362–7. doi: 10.1046/j.1365-2567.2001.01252.x
95
DuerschmiedDSuidanGLDemersMHerrNCarboCBrillAet al. Platelet serotonin promotes the recruitment of neutrophils to sites of acute inflammation in mice. Blood (2013) 121(6):1008–15. doi: 10.1182/blood-2012-06-437392
96
Leon-PonteMAhernGPO'ConnellPJ. Serotonin provides an accessory signal to enhance T-cell activation by signaling through the 5-HT7 receptor. Blood (2007) 109(8):3139–46. doi: 10.1182/blood-2006-10-052787
97
MaulerMHerrNSchoenichenCWitschTMarchiniTHardtnerCet al. Platelet serotonin aggravates myocardial Ischemia/Reperfusion injury via neutrophil degranulation. Circulation (2019) 139(7):918–31. doi: 10.1161/CIRCULATIONAHA.118.033942
98
WangMJHuangYHuangRYChenXMZhouYYYuWLet al. Determination of role of thromboxane A2 in rheumatoid arthritis. Discovery Med (2015) 19(102):23–32.
99
NaikMUPatelPDerstineRTuragaRChenXGollaKet al. Ask1 regulates murine platelet granule secretion, thromboxane A2 generation, and thrombus formation. Blood (2017) 129(9):1197–209. doi: 10.1182/blood-2016-07-729780
100
IshizukaTKawakamiMHidakaTMatsukiYTakamizawaMSuzukiKet al. Stimulation with thromboxane A2 (TXA2) receptor agonist enhances ICAM-1, VCAM-1 or ELAM-1 expression by human vascular endothelial cells. Clin Exp Immunol (1998) 112(3):464–70.
101
JenneCNKubesP. Platelets in inflammation and infection. Platelets (2015) 26(4):286–92. doi: 10.3109/09537104.2015.1010441
102
ChenYYuanYLiW. Sorting machineries: How platelet-dense granules differ from alpha-granules. Biosci Rep (2018) 38(5). doi: 10.1042/BSR20180458
103
BlairPFlaumenhaftR. Platelet alpha-granules: Basic biology and clinical correlates. Blood Rev (2009) 23(4):177–89. doi: 10.1016/j.blre.2009.04.001
104
SmithCW. Release of alpha-granule contents during platelet activation. Platelets (2022) 33(4):491–502. doi: 10.1080/09537104.2021.1913576
105
LarsenECeliAGilbertGEFurieBCErbanJKBonfantiRet al. PADGEM protein: A receptor that mediates the interaction of activated platelets with neutrophils and monocytes. Cell (1989) 59(2):305–12. doi: 10.1016/0092-8674(89)90292-4
106
SavageJSWilliamsCMKonopatskayaOHersIHarperMTPooleAW. Munc13-4 is critical for thrombosis through regulating release of ADP from platelets. J Thromb Haemost (2013) 11(4):771–5. doi: 10.1111/jth.12138
107
BoilardEBellioM. Platelet extracellular vesicles and the secretory interactome join forces in health and disease. Immunol Rev (2022) 312, (1):38–51. doi: 10.1111/imr.13119
108
GiannottaMTapeteGEmmiGSilvestriEMillaM. Thrombosis in inflammatory bowel diseases: what's the link? Thromb J (2015) 13:14. doi: 10.1186/s12959-015-0044-2
109
StockerTJIshikawa-AnkerholdHMassbergSSchulzC. Small but mighty: Platelets as central effectors of host defense. Thromb Haemost (2017) 117(4):651–61.
110
AntoniakSMackmanN. Platelets and viruses. Platelets (2021) 32(3):325–30. doi: 10.1080/09537104.2021.1887842
111
KimHConwayEM. Platelets and complement cross-talk in early atherogenesis. Front Cardiovasc Med (2019) 6:131. doi: 10.3389/fcvm.2019.00131
112
Hamzeh-CognasseHBerthelotPTardyBPozzettoBBourletTLaradiSet al. Platelet toll-like receptors are crucial sensors of infectious danger moieties. Platelets (2018) 29(6):533–40. doi: 10.1080/09537104.2018.1445842
113
AndoneguiGKerfootSMMcNagnyKEbbertKVPatelKDKubesP. Platelets express functional toll-like receptor-4. Blood (2005) 106(7):2417–23. doi: 10.1182/blood-2005-03-0916
114
EdilovaMIAkramAAbdul-SaterAA. Innate immunity drives pathogenesis of rheumatoid arthritis. BioMed J (2021) 44(2):172–82. doi: 10.1016/j.bj.2020.06.010
115
MottPJLazarusAH. CD44 antibodies and immune thrombocytopenia in the amelioration of murine inflammatory arthritis. PLoS One (2013) 8(6):e65805. doi: 10.1371/journal.pone.0065805
116
EndresenGK. Investigation of blood platelets in synovial fluid from patients with rheumatoid arthritis. Scand J Rheumatol (1981) 10(3):204–8. doi: 10.3109/03009748109095299
117
HutchinsonRMDavisPJaysonMI. Thrombocytosis in rheumatoid arthritis. Ann Rheum Dis (1976) 35(2):138–42. doi: 10.1136/ard.35.2.138
118
ErtenliIKirazSAriciMHaznedarogluICCalguneriMCelikIet al. P-selectin as a circulating molecular marker in rheumatoid arthritis with thrombocytosis. J Rheumatol (1998) 25(6):1054–8.
119
RooneyTScherzerRShigenagaJKGrafJImbodenJBGrunfeldC. Levels of plasma fibrinogen are elevated in well-controlled rheumatoid arthritis. Rheumatol (Oxford) (2011) 50(8):1458–65. doi: 10.1093/rheumatology/ker011
120
Mac MullanPAPeaceAJMadiganAMTedescoAFKennyDMcCarthyGM. Platelet hyper-reactivity in active inflammatory arthritis is unique to the adenosine diphosphate pathway: A novel finding and potential therapeutic target. Rheumatology (2010) 49(2):240–5. doi: 10.1093/rheumatology/kep377
121
SfikakisPPCharalambopoulosDVaiopoulosGMavrikakisM. Circulating p- and l-selectin and T-lymphocyte activation and patients with autoimmune rheumatic diseases. Clin Rheumatol (1999) 18(1):28–32. doi: 10.1007/s100670050047
122
GoulesATzioufasAGManousakisMNKirouKACrowMKRoutsiasJG. Elevated levels of soluble CD40 ligand (sCD40L) in serum of patients with systemic autoimmune diseases. J Autoimmun (2006) 26(3):165–71. doi: 10.1016/j.jaut.2006.02.002
123
TamuraNKobayashiSKatoKBandoHHarutaKOyanagiMet al. Soluble CD154 in rheumatoid arthritis: Elevated plasma levels in cases with vasculitis. J Rheumatol (2001) 28(12):2583–90.
124
MelkiIAllaeysITessandierNMailhotBCloutierNCampbellRAet al. FcgammaRIIA expression accelerates nephritis and increases platelet activation in systemic lupus erythematosus. Blood (2020) 136(25):2933–45. doi: 10.1182/blood.2020004974
125
MorganBPDanielsRHWilliamsBD. Measurement of terminal complement complexes in rheumatoid arthritis. Clin Exp Immunol (1988) 73(3):473–8.
126
ArgnaniLZanettiACarraraGSilvagniEGuerriniGZambonAet al. Rheumatoid arthritis and cardiovascular risk: Retrospective matched-cohort analysis based on the RECORD study of the Italian society for rheumatology. Front Med (Lausanne) (2021) 8:745601. doi: 10.3389/fmed.2021.745601
127
YoshimuraMFujiedaYSugawaraMKonoMKatoMYokotaIet al. Disease activity as a risk factor for venous thromboembolism in rheumatoid arthritis analysed using time-averaged DAS28CRP: A nested case-control study. Rheumatol Int (2022) 42, (11):1939–46. doi: 10.1007/s00296-022-05121-4
128
RenduFBrohard-BohnB. The platelet release reaction: granules' constituents, secretion and functions. Platelets (2001) 12(5):261–73. doi: 10.1080/09537100120068170
129
KaplanDRChaoFCStilesCDAntoniadesHNScherCD. Platelet alpha granules contain a growth factor for fibroblasts. Blood (1979) 53(6):1043–52. doi: 10.1182/blood.V53.6.1043.1043
130
ColciagoACelottiFCasatiLGiancolaRCastanoSMAntoniniGet al. In vitro effects of PDGF isoforms (AA, BB, AB and CC) on migration and proliferation of SaOS-2 osteoblasts and on migration of human osteoblasts. Int J BioMed Sci (2009) 5(4):380–9.
131
WangBHLuYHWuLFLuXGuoWDengFYet al. Evaluation of plasma cytokine protein array profile: The highlighted PDGF-BB in rheumatoid arthritis. Clin Rheumatol (2020) 39(11):3323–30. doi: 10.1007/s10067-020-05109-0
132
ShibuyaHYoshitomiHMurataKKobayashiSFuruMIshikawaMet al. TNFalpha, PDGF, and TGFbeta synergistically induce synovial lining hyperplasia via inducible PI3Kdelta. Mod Rheumatol (2015) 25(1):72–8. doi: 10.3109/14397595.2014.900847
133
RosengrenSCorrMBoyleDL. Platelet-derived growth factor and transforming growth factor beta synergistically potentiate inflammatory mediator synthesis by fibroblast-like synoviocytes. Arthritis Res Ther (2010) 12(2):R65. doi: 10.1186/ar2981
134
GraingerDJWakefieldLBethellHWFarndaleRWMetcalfeJC. Release and activation of platelet latent TGF-beta in blood clots during dissolution with plasmin. Nat Med (1995) 1(9):932–7. doi: 10.1038/nm0995-932
135
ZhuDZhaoJLouAHuangQOuYangQZhuJet al. Transforming growth factor beta1 promotes fibroblast-like synoviocytes migration and invasion via TGF-beta1/Smad signaling in rheumatoid arthritis. Mol Cell Biochem (2019) 459(1-2):141–50. doi: 10.1007/s11010-019-03557-0
136
AgereSAAkhtarNWatsonJMAhmedS. RANTES/CCL5 induces collagen degradation by activating MMP-1 and MMP-13 expression in human rheumatoid arthritis synovial fibroblasts. Front Immunol (2017) 8:1341. doi: 10.3389/fimmu.2017.01341
137
DanksLKomatsuNGuerriniMMSawaSArmakaMKolliasGet al. RANKL expressed on synovial fibroblasts is primarily responsible for bone erosions during joint inflammation. Ann Rheum Dis (2016) 75(6):1187–95. doi: 10.1136/annrheumdis-2014-207137
138
MauseSFvon HundelshausenPZerneckeAKoenenRRWeberC. Platelet microparticles: a transcellular delivery system for RANTES promoting monocyte recruitment on endothelium. Arterioscler Thromb Vasc Biol (2005) 25(7):1512–8. doi: 10.1161/01.ATV.0000170133.43608.37
139
SpragueDLElzeyBDCristSAWaldschmidtTJJensenRJRatliffTL. Platelet-mediated modulation of adaptive immunity: Unique delivery of CD154 signal by platelet-derived membrane vesicles. Blood (2008) 111(10):5028–36. doi: 10.1182/blood-2007-06-097410
140
WangWLiuJYangBMaZLiuGShenWet al. Modulation of platelet-derived microparticles to adhesion and motility of human rheumatoid arthritis fibroblast-like synoviocytes. PLoS One (2017) 12(7):e0181003. doi: 10.1371/journal.pone.0181003
141
WangWDengZLiuGYangJZhouWZhangCet al. Platelet-derived extracellular vesicles promote the migration and invasion of rheumatoid arthritis fibroblast-like synoviocytes via CXCR2 signaling. Exp Ther Med (2021) 22(4):1120. doi: 10.3892/etm.2021.10554
142
DemoruelleMKHarrallKKHoLPurmalekMMSetoNLRothfussHMet al. Anti-citrullinated protein antibodies are associated with neutrophil extracellular traps in the sputum in relatives of rheumatoid arthritis patients. Arthritis Rheumatol (2017) 69(6):1165–75. doi: 10.1002/art.40066
143
TanakaDKagariTDoiHShimozatoT. Essential role of neutrophils in anti-type II collagen antibody and lipopolysaccharide-induced arthritis. Immunology (2006) 119(2):195–202. doi: 10.1111/j.1365-2567.2006.02424.x
144
AssiLKWongSHLudwigARazaKGordonCSalmonMet al. Tumor necrosis factor alpha activates release of b lymphocyte stimulator by neutrophils infiltrating the rheumatoid joint. Arthritis Rheumatol (2007) 56(6):1776–86. doi: 10.1002/art.22697
145
ChakravartiARaquilMATessierPPoubellePE. Surface RANKL of toll-like receptor 4-stimulated human neutrophils activates osteoclastic bone resorption. Blood (2009) 114(8):1633–44. doi: 10.1182/blood-2008-09-178301
146
PiccardoniPEvangelistaVPiccoliAde GaetanoGWalzACerlettiC. Thrombin-activated human platelets release two NAP-2 variants that stimulate polymorphonuclear leukocytes. Thromb Haemost (1996) 76(5):780–5. doi: 10.1055/s-0038-1650660
147
Del ReyMJFareRIzquierdoEUsateguiARodriguez-FernandezJLSuarez-FueyoAet al. Clinicopathological correlations of podoplanin (gp38) expression in rheumatoid synovium and its potential contribution to fibroblast platelet crosstalk. PLoS One (2014) 9(6):e99607.
148
MetzemaekersMGouwyMProostP. Neutrophil chemoattractant receptors in health and disease: Double-edged swords. Cell Mol Immunol (2020) 17(5):433–50. doi: 10.1038/s41423-020-0412-0
149
DuchezACBoudreauLHNaikaGSBollingerJBelleanneeCCloutierNet al. Platelet microparticles are internalized in neutrophils via the concerted activity of 12-lipoxygenase and secreted phospholipase A2-IIA. Proc Natl Acad Sci U S A (2015) 112(27):E3564–73.
150
EvangelistaVManariniSSideriRRotondoSMartelliNPiccoliAet al. Platelet/polymorphonuclear leukocyte interaction: P-selectin triggers protein-tyrosine phosphorylation-dependent CD11b/CD18 adhesion: role of PSGL-1 as a signaling molecule. Blood. (1999) 93(3):876–85. doi: 10.1182/blood.V93.3.876
151
OstrovskyLKingAJBondSMitchellDLorantDEZimmermanGAet al. A juxtacrine mechanism for neutrophil adhesion on platelets involves platelet-activating factor and a selectin-dependent activation process. Blood. (1998) 91(8):3028–36. doi: 10.1182/blood.V91.8.3028.3028_3028_3036
152
SimonDIChenZXuHLiCQDongJMcIntireLVet al. Platelet glycoprotein ibalpha is a counterreceptor for the leukocyte integrin mac-1 (CD11b/CD18). J Exp Med (2000) 192(2):193–204. doi: 10.1084/jem.192.2.193
153
WrightSDWeitzJIHuangAJLevinSMSilversteinSCLoikeJD. Complement receptor type three (CD11b/CD18) of human polymorphonuclear leukocytes recognizes fibrinogen. Proc Natl Acad Sci U S A (1988) 85(20):7734–8. doi: 10.1073/pnas.85.20.7734
154
DurrantTNvan den BoschMTHersI. Integrin alphaIIbbeta3 outside-in signaling. Blood (2017) 130(14):1607–19. doi: 10.1182/blood-2017-03-773614
155
MutuaVGershwinLJ. A review of neutrophil extracellular traps (NETs) in disease: Potential anti-NETs therapeutics. Clin Rev Allergy Immunol (2021) 61(2):194–211. doi: 10.1007/s12016-020-08804-7
156
MaugeriNCampanaLGavinaMCovinoCDe MetrioMPanciroliCet al. Activated platelets present high mobility group box 1 to neutrophils, inducing autophagy and promoting the extrusion of neutrophil extracellular traps. J Thromb Haemost (2014) 12(12):2074–88. doi: 10.1111/jth.12710
157
ClarkSRMaACTavenerSAMcDonaldBGoodarziZKellyMMet al. Platelet TLR4 activates neutrophil extracellular traps to ensnare bacteria in septic blood. Nat Med (2007) 13(4):463–9. doi: 10.1038/nm1565
158
XieCBJane-WitDPoberJS. Complement membrane attack complex: New roles, mechanisms of action, and therapeutic targets. Am J Pathol (2020) 190(6):1138–50. doi: 10.1016/j.ajpath.2020.02.006
159
HolersVMBandaNK. Complement in the initiation and evolution of rheumatoid arthritis. Front Immunol (2018) 9:1057. doi: 10.3389/fimmu.2018.01057
160
KonttinenYTCeponisAMeriSVuorikoskiAKortekangasPSorsaTet al. Complement in acute and chronic arthritides: Assessment of C3c, C9, and protectin (CD59) in synovial membrane. Ann Rheum Dis (1996) 55(12):888–94. doi: 10.1136/ard.55.12.888
161
ReisESChenHSfyroeraGMonkPNKohlJRicklinDet al. C5a receptor-dependent cell activation by physiological concentrations of desarginated C5a: insights from a novel label-free cellular assay. J Immunol (2012) 189(10):4797–805. doi: 10.4049/jimmunol.1200834
162
SagguGCortesCEmchHNRamirezGWorthRGFerreiraVP. Identification of a novel mode of complement activation on stimulated platelets mediated by properdin and C3(H2O). J Immunol (2013) 190(12):6457–67. doi: 10.4049/jimmunol.1300610
163
Del CondeICruzMAZhangHLopezJAAfshar-KharghanV. Platelet activation leads to activation and propagation of the complement system. J Exp Med (2005) 201(6):871–9. doi: 10.1084/jem.20041497
164
KozarcaninHLoodCMunthe-FogLSandholmKHamadOABengtssonAAet al. The lectin complement pathway serine proteases (MASPs) represent a possible crossroad between the coagulation and complement systems in thromboinflammation. J Thromb Haemost (2016) 14(3):531–45. doi: 10.1111/jth.13208
165
LeyK. M1 means kill; M2 means heal. J Immunol (2017) 199(7):2191–3. doi: 10.4049/jimmunol.1701135
166
MulherinDFitzgeraldOBresnihanB. Synovial tissue macrophage populations and articular damage in rheumatoid arthritis. Arthritis Rheumatol (1996) 39(1):115–24. doi: 10.1002/art.1780390116
167
MisharinAVCudaCMSaberRTurnerJDGierutAKHainesGK3rdet al. Nonclassical Ly6C(-) monocytes drive the development of inflammatory arthritis in mice. Cell Rep (2014) 9(2):591–604. doi: 10.1016/j.celrep.2014.09.032
168
KuijperPHGallardo TorresHIHoubenLALammersJWZwagingaJJKoendermanL. P-selectin and MAC-1 mediate monocyte rolling and adhesion to ECM-bound platelets under flow conditions. J Leukoc Biol (1998) 64(4):467–73. doi: 10.1002/jlb.64.4.467
169
HamadOAEkdahlKNNilssonPHAnderssonJMagottiPLambrisJDet al. Complement activation triggered by chondroitin sulfate released by thrombin receptor-activated platelets. J Thromb Haemost (2008) 6(8):1413–21. doi: 10.1111/j.1538-7836.2008.03034.x
170
MartinsPvan GilsJMMolAHordijkPLZwagingaJJ. Platelet binding to monocytes increases the adhesive properties of monocytes by up-regulating the expression and functionality of beta1 and beta2 integrins. J Leukoc Biol (2006) 79(3):499–507. doi: 10.1189/jlb.0605318
171
SantosoSSachsUJKrollHLinderMRufAPreissnerKTet al. The junctional adhesion molecule 3 (JAM-3) on human platelets is a counterreceptor for the leukocyte integrin mac-1. J Exp Med (2002) 196(5):679–91. doi: 10.1084/jem.20020267
172
WangYSakumaMChenZUstinovVShiCCroceKet al. Leukocyte engagement of platelet glycoprotein ibalpha via the integrin mac-1 is critical for the biological response to vascular injury. Circulation. (2005) 112(19):2993–3000. doi: 10.1161/CIRCULATIONAHA.105.571315
173
WeyrichASMcIntyreTMMcEverRPPrescottSMZimmermanGA. Monocyte tethering by p-selectin regulates monocyte chemotactic protein-1 and tumor necrosis factor-alpha secretion. signal integration and NF-kappa b translocation. J Clin Invest. (1995) 95(5):2297–303.
174
GierutAPerlmanHPopeRM. Innate immunity and rheumatoid arthritis. Rheum Dis Clin North Am (2010) 36(2):271–96. doi: 10.1016/j.rdc.2010.03.004
175
MeradMSathePHelftJMillerJMorthaA. The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting. Annu Rev Immunol (2013) 31:563–604. doi: 10.1146/annurev-immunol-020711-074950
176
VictoratosPKolliasG. Induction of autoantibody-mediated spontaneous arthritis critically depends on follicular dendritic cells. Immunity (2009) 30(1):130–42. doi: 10.1016/j.immuni.2008.10.019
177
ElzeyBDTianJJensenRJSwansonAKLeesJRLentzSRet al. Platelet-mediated modulation of adaptive immunity. a communication link between innate and adaptive immune compartments. Immunity (2003) 19(1):9–19. doi: 10.1016/S1074-7613(03)00177-8
178
DuffauPSeneschalJNiccoCRichezCLazaroEDouchetIet al. Platelet CD154 potentiates interferon-alpha secretion by plasmacytoid dendritic cells in systemic lupus erythematosus. Sci Transl Med (2010) 2(47):47ra63.
179
RoelofsMFWeninkMHBrentanoFAbdollahi-RoodsazSOppers-WalgreenBBarreraPet al. Type I interferons might form the link between toll-like receptor (TLR) 3/7 and TLR4-mediated synovial inflammation in rheumatoid arthritis (RA). Ann Rheum Dis (2009) 68(9):1486–93. doi: 10.1136/ard.2007.086421
180
RoggeLD'AmbrosioDBiffiMPennaGMinettiLJPreskyDHet al. The role of Stat4 in species-specific regulation of Th cell development by type I IFNs. J Immunol (1998) 161(12):6567–74.
181
McRaeBLSemnaniRTHayesMPvan SeventerGA. Type I IFNs inhibit human dendritic cell IL-12 production and Th1 cell development. J Immunol (1998) 160(9):4298–304.
182
VivierEArtisDColonnaMDiefenbachADi SantoJPEberlGet al. Innate lymphoid cells: 10 years on. Cell (2018) 174(5):1054–66. doi: 10.1016/j.cell.2018.07.017
183
BalSMGolebskiKSpitsH. Plasticity of innate lymphoid cell subsets. Nat Rev Immunol (2020) 20(9):552–65. doi: 10.1038/s41577-020-0282-9
184
ColonnaM. Innate lymphoid cells: Diversity, plasticity, and unique functions in immunity. Immunity (2018) 48(6):1104–17. doi: 10.1016/j.immuni.2018.05.013
185
FangWZhangYChenZ. Innate lymphoid cells in inflammatory arthritis. Arthritis Res Ther (2020) 22(1):25. doi: 10.1186/s13075-020-2115-4
186
OmataYFrechMPrimbsTLucasSAndreevDScholtysekCet al. Group 2 innate lymphoid cells attenuate inflammatory arthritis and protect from bone destruction in mice. Cell Rep (2018) 24(1):169–80. doi: 10.1016/j.celrep.2018.06.005
187
OrimoKTamariMTakedaTKuboTRuckertBMotomuraKet al. Direct platelet adhesion potentiates group 2 innate lymphoid cell functions. Allergy (2022) 77(3):843–55. doi: 10.1111/all.15057
188
KartaMRCavagneroKMillerMBadraniJNajiLDohertyTAet al. Platelets attach to lung type 2 innate lymphoid cells (ILC2s) expressing p-selectin glycoprotein ligand 1 and influence ILC2 function. J Allergy Clin Immunol (2019) 144(4):1112–5.e8. doi: 10.1016/j.jaci.2019.06.001
189
CafaroGBartoloniEAlunnoAGerliR. Platelets: A potential target for rheumatoid arthritis treatment? Expert Rev Clin Immunol (2019) 15(1):1–3. doi: 10.1080/1744666X.2019.1544071
Summary
Keywords
platelets, rheumatoid arthritis, inflammation, cell signaling, cytokines
Citation
Jiang SZ, To JL, Hughes MR, McNagny KM and Kim H (2022) Platelet signaling at the nexus of innate immunity and rheumatoid arthritis. Front. Immunol. 13:977828. doi: 10.3389/fimmu.2022.977828
Received
24 June 2022
Accepted
03 October 2022
Published
25 November 2022
Volume
13 - 2022
Edited by
Zhu Chen, University of Science and Technology of China, China
Reviewed by
Aline Bozec, University of Erlangen Nuremberg, Germany
Updates
Copyright
© 2022 Jiang, To, Hughes, McNagny and Kim.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Hugh Kim, hughkim@dentistry.ubc.ca
This article was submitted to Autoimmune and Autoinflammatory Disorders, a section of the journal Frontiers in Immunology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.